Riesgo de acidosis láctica fatal y no fatal con el uso de metformina para la diabetes mellitus tipo 2
Characteristics of included studies Notes Allocation concealment
D
Study
Jones 2002
Methods
TRIAL DESIGN: Double-blind randomised controlled trial DURATION: 4 months
Participants
COUNTRY: United States SETTING: outpatient Treatment N: 42 Control N: 40 Age: 14 +/- 1.8 Sex: 30% men Inclusion: pediatric patients age 10-16 with type 2 DM Exclusions: creatinine > 76 mcmole/L, hepatic dysfunction
Interventions
TREATMENT: metformin up to 2 g/day COMPARISON: placebo
Outcomes
Fasting glucose, HbA1c
Notes Allocation concealment
D
Study
Josephkutty 1990
Methods
TRIAL DESIGN: Double-blind randomised controlled trial DURATION: 3 months
Participants
COUNTRY: United Kingdom SETTING: outpatient Treatment N: 20 Control N: 20 Treatment AGE: 76.5 Control AGE: 80.5 Treatment SEX: 30% men Control SEX: 30% men INCLUSION: Type 2 DM patients, aged 65 or older EXCLUSIONS: renal or liver function abnormalities, recent congestive heart failure
Interventions
TREATMENT: Metformin 1g BID COMPARISON: tolbutamide
Outcomes
Fasting insulin, glucose, lactate levels, lipids and weight.
Notes Allocation concealment
B
Study
Josse 1995
Methods
TRIAL DESIGN: randomised controlled trial of acarbose versus placebo. Metformin in nonrandomised treatment strata DURATION: 12 months
Página 63
Copyright © John Wiley & Sons Ltd. Usado con permiso de John Wiley & Sons, Ltd.